25I-NBF: 25I-NBF is approximately 6-8 times less potent than 25I-NBOMe but shares a similar qualitative effect profile and comparable safety concerns. Primary activity occurs through potent partial agonism at 5-HT2A and 5-HT2C receptors with bias toward β-arrestin 2 signaling; peripheral α-adrenergi
Related pages